Baseline left atrial volume as a potential predictor of trastuzumab related cardiotoxicity in her 2 positive breast cancer patients

被引：0
|
作者：
Dolci, G. [1 ]
Bergamini, C. [1 ]
Benfari, G. [1 ]
Torelli, F. [1 ]
Ghiselli, L. [1 ]
Rossi, A. [1 ]
Trevisani, L. [1 ]
Truong, S. [1 ]
Vinco, G. [1 ]
La Russa, F. [2 ]
Molino, A. [2 ]
Vassanelli, C. [1 ]
机构：
[1] Univ Verona, Sect Cardiol, Dept Med, Verona, Italy
[2] Civil Hosp Maggiore Borgo Trento, Oncol, Verona, Italy
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P569
引用
收藏
页码：99 / 99
页数：1
相关论文
共 50 条
  • [21] Risk factors and clinical relevance of cardiotoxicity in her2 positive breast cancer patients treated with trastuzumab
    Minguito Carazo, C. Carlos
    Lopez Flores, M.
    Sanchez Cousido, L. F.
    Lopez Gonzalez, A.
    Rodriguez Santamarta, M.
    Tundidor Sanz, E.
    Echarte Morales, J.
    Sanchez Munoz, E.
    Garcia Palomo, A.
    Fernandez Vazquez, F.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 37 - 37
  • [22] Cardiotoxicity in HER-2 positive patients, with advanced breast cancer, receiving several years of treatment with trastuzumab
    Larsen, A. K.
    Jensen, A. B.
    Langkjer, S. T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S183 - S184
  • [23] Evaluation of early cardiotoxicity in HER2-positive breast cancer patients receiving radiotherapy and concurrent trastuzumab
    Aslan, Dicle
    Ozoner, Sadik
    Inanc, Mevlude
    Yildiz, Oguz Galip
    Inanc, Mehmet Tugrul
    IRISH JOURNAL OF MEDICAL SCIENCE, 2025, 194 (01) : 7 - 18
  • [24] Trastuzumab in metastatic HER2+ breast cancer: cardiotoxicity
    Reactions Weekly, 2020, 1794 (1) : 12 - 12
  • [25] Left atrial global longitudinal strain as a new predictor of cardiotoxicity in breast cancer patients
    Park, H.
    Kim, M.
    Jeong, H. K.
    Kim, K. H.
    Kim, H. Y.
    Cho, J. Y.
    Yoon, H. J.
    Ahn, Y.
    Jeong, M. H.
    Cho, J. G.
    Park, J. C.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1272 - 1272
  • [26] Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
    Bonardeaux, Orianne de la Brassinne
    Born, Benjamin
    Moonen, Marie
    Lancellotti, Patrizio
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (21)
  • [27] Rates of trastuzumab-associated cardiotoxicity in patients with HER2-positive breast cancer at a tertiary cancer centre.
    Tyagi, Nidhi Kumar
    Arora, Roochi
    Partridge, Arun
    Tharmabala, Mithula
    Mukherjee, Som
    Leong, Darryl
    Dhesy-Thind, Sukhbinder K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] HER2/neu 655 polymorphism, trastuzumab-induced cardiotoxicity, and survival in HER2-positive breast cancer patients
    Blancas, Isabel
    Linares-Rodriguez, Marina
    Martin-Bravo, Celia
    Gomez-Pena, Celia
    Rodriguez-Serrano, Fernando
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (10): : 2531 - 2540
  • [29] Left ventricular end-diastolic volume as an early indicator of Trastuzumab-related cardiotoxicity in patients with HER2 positive breast cancer: results from a single-center retrospective study
    Torelli, F.
    Bergamini, C.
    Ghiselli, L.
    Rossi, A.
    Trevisani, L.
    Vinco, G.
    Troung, S.
    Benfari, G.
    La Russa, F.
    Golia, G.
    Molino, A.
    Vassanelli, C.
    EUROPEAN HEART JOURNAL, 2016, 37 : 426 - 426
  • [30] The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction
    Bouwer, Nathalie, I
    Steenbruggen, Tessa G.
    Rier, Hanah N.
    Kitzen, Jos J. E. M.
    Smorenburg, Carolien H.
    van Bekkum, Marlies L.
    de Jong, Paul C.
    Drooger, Jan C.
    Holterhues, Cynthia
    Kofflard, Marcel J. M.
    Boersma, Eric
    Sonke, Gabe S.
    Levin, Mark-David
    Jager, Agnes
    INTERNATIONAL JOURNAL OF CANCER, 2022, 151 (04) : 616 - 622
12345